Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A succinct guide to identifying the ETF with the best tax efficiency for dividend exposure, including key considerations and quick decision tips.
28,132 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Chip stocks are rising on AI infrastructure strength even as software names sag, hinting at a broader market rotation...
HSBC upgraded Cisco to Buy and lifted the price target as the company moves toward a $6 billion AI revenue goal for F...
XRP traders are watching a narrow price corridor as Ripple eyes a breakout. With critical support near $1.30 and resi...
A policy push to cover GLP-1 drugs for weight loss under Medicare stalled, leaving many beneficiaries in the middle. ...
Cisco stock has surged about 32% in the past 30 days as AI infrastructure demand climbs; Arista slid 10% and Broadcom...
New grads confront a tight job market as AI reshapes hiring. A veteran who weathered the 2008 crash offers a practica...
Regulators in Europe, the United States, and Asia are escalating the debate over how stablecoins fit into the future ...
CrowdStrike has become a pillar in AI-era cybersecurity, but a 14% decline raises the question: is it a buy? This gui...
With the MiCA deadline looming, a vast majority of EU crypto firms have not completed full licensing. Only a fraction...
Retail buyers piled into SpaceX shares over a two-day window, creating a record pace that outstripped every other U.S...
A Portland, Oregon court filing shows Compass has settled the Murch TCPA lawsuit. The terms are confidential, and a n...